Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the evidence actually shows about tolerability on each medicine
The misconception: Mounjaro's dual mechanism makes it harder to tolerate
A common assumption is that because Mounjaro (tirzepatide) activates two receptors (GIP and GLP-1) it must deliver a double dose of side effects compared with Wegovy (semaglutide), which targets GLP-1 alone. The trial data does not support that cleanly. In SURMOUNT-1, published in the New England Journal of Medicine, the most common adverse events at tirzepatide's highest doses were nausea, diarrhoea and vomiting, the same GI-led cluster seen in Wegovy's STEP trials. Rates were broadly comparable rather than dramatically elevated.
The better question is not which medicine is categorically worse, but which profile of effects is more predictable for a given person at a given dose. GIP receptor activity may actually moderate some of the nausea associated with GLP-1 stimulation alone, which could partly explain why some people find tirzepatide tolerable at higher doses than expected. That said, individual variation is large. Two people on the same pen can have very different first weeks.
One practical tip worth doing in under a minute: before your first injection, read through the side-effect section of the Patient Information Leaflet included in your pen box. Knowing in advance that mild nausea on day two or three is documented (and typically settles) removes a lot of anxiety when it happens.
Where the two medicines genuinely differ on tolerability
The GI side-effect profiles overlap heavily: nausea, constipation, diarrhoea, reflux and fatigue appear on both medicines' NHS information pages for tirzepatide and semaglutide. The timing tends to follow dose increases on both, with symptoms most noticeable in the first week or two after a step up, then settling.
Where a real difference exists is injection-site reactions and the contraception interaction. Tirzepatide's SmPC notes that women using oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because gut-slowing may reduce pill absorption. NHS England's guidance on weight-management injections extends this to considering transdermal HRT for the same reason. Semaglutide does not carry an equivalent evidence-based warning on oral contraception. This is not a side effect in the traditional sense, but it is a clinically significant difference in tolerability planning.
In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but serious risk across GLP-1 medicines. The symptom to act on immediately is severe, persistent stomach pain that may spread to the back. That warning applies to both medicines equally, it is not a distinguishing factor between them.
Comparing the profiles: a factual summary
| Side effect | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Nausea | Common, especially at dose increases; typically settles within 1–2 weeks | Common, same pattern; most frequent at 1.7mg and 2.4mg steps |
| Diarrhoea / constipation | Both reported; constipation slightly more noted at higher doses | Both reported; diarrhoea more frequently cited in STEP trial data |
| Vomiting | Less common than nausea; more likely at faster titration | Less common than nausea; same pattern |
| Oral contraceptive interaction | Add barrier method first 4 weeks of treatment and after each dose increase [Source: NHS England] | No equivalent documented reduction in pill absorption |
| Pancreatitis risk | Infrequent but serious; urgent help for severe back-radiating abdominal pain [Source: MHRA DSU, Jan 2026] | Same infrequent but serious risk; same urgent-help rule |
| Injection-site reactions | Mild redness or bruising; rotate sites (abdomen, thigh, upper arm) | Mild redness or bruising; same rotation advice |
If you'd like a deeper read on how people's experiences compare across the two, our page on Mounjaro and Wegovy side effects goes into more detail on managing each symptom type. If you are specifically wondering whether Wegovy side effects are worse than Mounjaro, we look at that question directly using the available trial evidence. Questions about cost differences are covered separately on our Wegovy vs Mounjaro cost page.
What this means when choosing between them
For most people the tolerability difference is small enough that it should not be the deciding factor on its own. Efficacy data from the SURMOUNT-5 trial showed tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, but if you have a strong history of GI sensitivity, or the oral-contraceptive interaction creates a practical problem, that shifts the balance. Neither of those points is a reason to avoid treatment; they are reasons to discuss it with a prescriber who knows your full picture.
Our clinical team, details of whose approach you can read on the clinical team page, reviews every consultation personally (a real prescriber, not an automated queue) and that is where the suitability question gets answered properly. If you are weighing up whether one of these medicines suits you, reading about how Wegovy and Mounjaro side effects compare in practice is a useful starting point before you book, and our detailed Wegovy vs Mounjaro side effects breakdown covers the evidence in full for those who want to go further. When you are ready, check your eligibility and one of our prescribers will review your consultation the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.